Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.
Cabometyx is the third liver cancer drug approved in the past six months.
Four out of 10 FDA workers are sidelined.
A second immunotherapy option is now available for hepatocellular carcinoma.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Lenvima works as well as standard therapy for metastatic or unresectable cancer.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Lucemyra is approved to treat the symptoms of opioid withdrawal for 14 days.
The Phase IIa trial will test the drug CC-31244 in combination with approved hepatitis C medications.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.
The two-drug regimen can cure the virus in as little as eight weeks.
Mike Sauers works for the U.S. Food and Drug Administration, and is one of more than 79,000 individuals who make HHS run every day.
The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.
The single-tablet regimen was just approved for adolsecent pediatric use in the United States.
The survival benefits over a placebo are modest, however.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.